Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.55 |
| ▸ | BRAF | P15056 | 5/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406941 | 0.89 | SLC2A1 (0.59) | RETSLC2A1FLT3AURKAKDR | |
| SCHEMBL14681237 | 0.87 | RET (0.61) | RETBRAFSLC2A1FLT3NPC1 | |
| SCHEMBL4708561 | 0.85 | MERTK (0.48) | KDR | |
| SCHEMBL4257158 | 0.84 | CD274 (0.44) | BRAFKDR | |
| SCHEMBL4268623 | 0.83 | EPHX2 (0.45) | KDR | |
| SCHEMBL4264563 | 0.83 | EPHX2 (0.46) | KDR | |
| SCHEMBL4259407 | 0.78 | KDR (0.54) | RETBRAFFLT3KDR | |
| SCHEMBL1257507 | 0.78 | FLT3 (0.57) | RETBRAFSLC2A1FLT3AURKA | |
| SCHEMBL4261490 | 0.77 | MERTK (0.52) | — | |
| SCHEMBL1256177 | 0.77 | SLC2A1 (0.62) | RETSLC2A1FLT3AURKAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432714-B1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-08-06 | — | — | EP | claimed |
| US-20070293489-A1 | Substituted Pyrazolopyrimidines | ADAMS JERRY | 2007-12-20 | — | — | US | claimed |
| US-7217710-B2 | Substituted pyrazolopyrimidines | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-15 | — | — | US | claimed |
| US-20040198751-A1 | Pyrazolo-pyrimidine compound; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | claimed |
| US-20090029989-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | ADAMS JERRY LEROY | 2009-01-29 | — | — | US | disclosed |
| EP-1432714-B1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070293489-A1 | Substituted Pyrazolopyrimidines | ADAMS JERRY | 2007-12-20 | — | — | US | disclosed |
| US-7217710-B2 | Substituted pyrazolopyrimidines | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-15 | — | — | US | disclosed |
| US-20040198751-A1 | Pyrazolo-pyrimidine compound; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293489-A1 | Substituted Pyrazolopyrimidines | DPYD, TPMT, TYMP | RET 2015/4885BRAF 154/4885SLC2A1 3037/4885 |
| US-20090029989-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | DPYD, TPMT, TYMP | RET 2015/4885BRAF 154/4885SLC2A1 3037/4885 |
| US-20040198751-A1 | Pyrazolo-pyrimidine compound; anticancer agents | DPYD, TYMP, TYMS | RET 1152/4885BRAF 30/4885SLC2A1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.